Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $1.42 USD
Change Today +0.05 / 3.65%
Volume 592.8K
ISR On Other Exchanges
As of 8:04 PM 08/28/15 All times are local (Market data is delayed by at least 15 minutes).

isoray inc (ISR) Snapshot

Previous Close
Day High
Day Low
52 Week High
05/21/15 - $3.79
52 Week Low
10/16/14 - $1.22
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for ISORAY INC (ISR)

Related News

No related news articles were found.

isoray inc (ISR) Related Businessweek News

No Related Businessweek News Found

isoray inc (ISR) Details

IsoRay, Inc develops, manufactures, and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States. The company produces Proxcelan Cesium-131 brachytherapy seeds for the treatment of prostate, lung, head and neck, colorectal, brain, pelvic/abdominal, and gynecological cancers, as well as ocular melanoma. It also offers GliaSite radiation therapy system, a balloon catheter device, which is used to treat brain cancer, including primary and recurrent gliomas and metastic brain tumors. The company is headquartered in Richland, Washington.

37 Employees
Last Reported Date: 09/29/14

isoray inc (ISR) Top Compensated Officers

Chairman and Chief Executive Officer
Total Annual Compensation: $334.7K
Chief Financial Officer
Total Annual Compensation: $117.8K
Vice President of Research & Development and ...
Total Annual Compensation: $154.5K
Compensation as of Fiscal Year 2014.

isoray inc (ISR) Key Developments

IsoRay Seeks Acquisitions

IsoRay, Inc. (AMEX:ISR) has filed a shelf registration in the amount of $20 million. IsoRay said, "We currently intend to use the net proceeds from the sale of securities offered by us pursuant to this prospectus for working capital, capital expenditures, research and development, and other general corporate purposes. We may also use such proceeds to fund acquisitions of businesses, technologies or product lines that complement our current business."

Chicago Prostate Cancer Center Selects Cesium 131 of IsoRay for Use in the Launch of a Study of the Focal Treatment of Prostate Cancer

IsoRay, Inc. announced that Dr. Brian J. Moran, Director of Chicago Prostate Cancer Center in Westmont, Illinois, has initiated a study of focal prostate cancer treatment using Cesium-131 brachytherapy. Focal therapy is treatment directed solely at the malignancy and its immediate surrounding tissue, rather than the entire gland or organ that is involved. The goal of focal therapy for prostate cancer is to eliminate the targeted cancer while sparing men the side effects that often come with whole gland treatment.

Glancy Prongay & Murray LLP Files Class Action Complaint against IsoRay, Inc

Glancy Prongay & Murray LLP announced that a class action complaint has been filed on behalf of a class comprising purchasers of the securities of IsoRay, Inc. between May 20, 2015 and May 21, 2015, inclusive. This class action seeks to recover damages against defendants for alleged violations of the federal securities laws. IsoRay investors have until July 21, 2015 to file a motion for appointment as a lead plaintiff. The complaint alleges that the company misled investors regarding clinical data concerning Cesium-131, by falsely reporting a 100% survival rate for Cesium-131 patients. On May 21, 2015, published a report entitled, ‘IsoRay Takes Liberties With Lung Cancer Study Results to Prop Up Stock Price.’ The report stated that, ‘IsoRay (ISR Get Report) does a poor job selling radioactive `seeds' for use in cancer radiation therapy. To make up for the inability to deliver revenue growth and prop up its stock price IsoRay issues a lot of promotional press releases, some of which take liberties with clinical data using clever, selective editing.’ The report continues, ‘IsoRay also plays rope-a-dope with the five-year overall survival rate of 100% for Cesium-131 patients. The company fails to mention the comparable five-year survival rate for patients undergoing surgery alone is 98% a clinically meaningless difference of two percentage points. Moreover, the survival analysis is severely limited because nearly every patient in the study is censored, meaning they're lost to follow up. The study does not conclude that treatment with Cesium-131 leads to longer survival.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ISR:US $1.42 USD +0.05

ISR Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ISR.
View Industry Companies

Industry Analysis


Industry Average

Valuation ISR Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 18.9x
Price/Book 3.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales 16.5x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ISORAY INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at